Metastatic Melanoma News

New Drug for Advanced Melanoma: Potential Breakthrough - Ivanhoe



French Tribune 
New Drug for Advanced Melanoma: Potential Breakthrough 
Ivanhoe
Dabrafenib blocks the activity of the cancer-causing mutated form of the BRAF gene, which is seen in about half of melanomas. BRAF is a known oncogene, a gene that when mutated causes cancer. About 50% of patients with metastatic melanoma have a BRAF ...
Texas Sized Results for Melanoma Drug Trial dailyRx
Phase I clinical trial shows drug shrinks melanoma brain metastases Eureka! Science News
Promising melanoma drug shrinks brain tumor allvoices
French Tribune  -ScienceAlert  -The Australian 
all 9 news articles » 


Dabrafenib Safe in Melanoma With Brain Mets - MedPage Today



TopNews United States 
Dabrafenib Safe in Melanoma With Brain Mets 
MedPage Today
In a phase I trial, dabrafenib treatment (150 mg twice daily) elicited responses in 69% (95% CI 51.9 to 83.7) and confirmed responses in 50% (95% CI 32.9 to 67.1) of 36 patients with the most common form of BRAF-mutated metastatic melanoma, ...
ASCO: Dabrafenib/Trametinib active in metastatic melanoma Medical Xpress
GSK melanoma drug shows promise in early trial Chicago Tribune
Two-Drug Combo May Be Safe for Melanoma Treatment Health.com
TopNews United States 
all 51 news articles » 


ASCO: Dabrafenib/Trametinib Active in Metastatic Melanoma - Doctors Lounge



Updated News 
ASCO: Dabrafenib/Trametinib Active in Metastatic Melanoma 
Doctors Lounge
For patients with V600 BRAF-mutant solid tumors, treatment with the oral BRAF inhibitor dabrafenib and the oral MEK 1/2 inhibitor trametinib is tolerated and has clinical activity in BRAF inhibitor-naive metastatic melanoma, according to a study ...
Melanoma Agent Surprise: Brain Tumors Shrink Too Medscape
Molecular Screening Awareness Grows in Step with Adoption of Roche Melanoma ... GenomeWeb
Double-Barrel Tx Effective for Melanoma MedPage Today
Skin and Allergy News Digital Network  -7thSpace Interactive (press release)  -U.S. News & World Report 
all 57 news articles » 


Galectin Therapeutics Announces Initiation of Phase 1/2 Trial of Novel ... - MarketWatch (press release)



Galectin Therapeutics Announces Initiation of Phase 1/2 Trial of Novel ... 
MarketWatch (press release)
"The initiation of this trial is an important step in evaluating a potential new treatment modality for patients with advanced metastatic melanoma, who experience limited success with currently available therapies." "Galectin Therapeutics is committed ...

and more » 


Melanoma Metastasis Test - dailyRx



Melanoma Metastasis Test 
dailyRx
The most important treatment for melanoma is complete removal before metastasis. At that point survival is 98 percent. The odds aren't so good for metastatic melanoma, skin cancer that has spread to other parts of the body, because no effective ...

 


Galectin Therapeutics Announces Initiation of Phase 1/2 Trial of Novel ... - EON: Enhanced Online News (press release)



Galectin Therapeutics Announces Initiation of Phase 1/2 Trial of Novel ... 
EON: Enhanced Online News (press release)
?The initiation of this trial is an important step in evaluating a potential new treatment modality for patients with advanced metastatic melanoma, who experience limited success with currently available therapies.? ?This first-in-human Phase 1/2 study ...

and more » 


SHOAF, SCOTT - San Francisco Chronicle



SHOAF, SCOTT 
San Francisco Chronicle
Scott Alan Shoaf May 21, 1941 - May 3, 2012 Scott Shoaf died peacefully at home in Lincoln, ending a 4 month valiant struggle against metastatic melanoma. Born in San Francisco, the middle child of Beth and Ross Shoaf, Scott grew up in Eureka Valley, ...

 


Metastatic Melanoma: Timely Approval of Yervoy - OncLive



OncLive 
Metastatic Melanoma: Timely Approval of Yervoy 
OncLive
... revealed progressive disease, and the decision was made to switch him to the immunotherapeutic agent Yervoy (ipilimumab; IV infusion [3 mg/kg] every 21 days for 4 cycles), which had just been approved for the treatment of metastatic melanoma.

 


Altor BioScience and the Melanoma Research Alliance to Co-Support Clinical ... - MarketWatch (press release)



Altor BioScience and the Melanoma Research Alliance to Co-Support Clinical ... 
MarketWatch (press release)
MIRAMAR, Fla., Apr 30, 2012 (BUSINESS WIRE) -- Altor BioScience Corporation (Altor), a leading developer of immunotherapeutics for curative treatment of metastatic malignancies, announced today that it will jointly sponsor with the Melanoma Research ...
Altor, MRA to jointly sponsor studies of ALT-803 against metastatic melanoma Pharmaceutical Business Review

all 8 news articles » 


Provectus Pharmaceuticals Forms Independent Board to Meet Corporate Governance ... - EON: Enhanced Online News (press release)



Provectus Pharmaceuticals Forms Independent Board to Meet Corporate Governance ... 
EON: Enhanced Online News (press release)
?As Provectus advances its clinical development programs, Dr. Wachter, in his new position as Chief Technology Officer, will be an instrumental part of our preparation for anticipated Phase 3 clinical testing of PV-10 for metastatic melanoma, ...

and more »